HAMP and inflammatory bowel disease: Hepcidin has already been proposed as a biomarker to guide iron therapy for non‐pregnant populations in specific clinical scenarios, including cases of haemodialysis patients,42 chronic rheumatologic disease,43 and inflammatory bowel disease (IBD).8